跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,197 条关于
“AKT-FOXM1”
全部
6,197
临床试验
3,608
药物
589
机构
75
资讯
1,925
去年
QPOP Platform Shows 87% Success Rate in Personalizing AML Treatment Selection
去年
Ryvu Therapeutics Discovers Synergistic mTOR-AKT Inhibitor Combination for Colorectal Cancer Treatment
11个月前
Enara Bio Unveils DARKFOX Dark Antigen for Solid Tumor Immunotherapy at SITC 2025
2年前
AstraZeneca's Truqap (capivasertib) Launched in Korea as First AKT Inhibitor for Breast Cancer
上个月
China's NMPA Accepts New Drug Application for Laekna's AKT Inhibitor Afuresertib in HR+/HER2- Breast Cancer
7个月前
Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR
3个月前
Vaderis Raises $152 Million to Fund Phase 3 Trial of AKT Inhibitor Engasertib in Hereditary Haemorrhagic Telangiectasia
去年
EZH2 and AKT Inhibitor Combination Shows Promise in Triple-Negative Breast Cancer
8个月前
Enara Bio Strengthens Dark Antigen Platform with Expanded Boehringer Partnership and New CMO Ahead of ENA101 Clinical Entry
去年
Atavistik Bio Doses First Patient in Phase 1 Trial of ATV-1601 for AKT1 E17K-Mutant Solid Tumors
第 1 页,共 193 页
上一页
下一页